Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reissued by stock analysts at Piper Jaffray Companies in a report released on Monday, Stock Target Advisor reports. They presently have a $104.00 price target on the stock. Piper Jaffray Companies’ price target suggests a potential upside of 57.70% from the company’s previous close.
Several other analysts also recently issued reports on CRSP. Goldman Sachs Group upped their price objective on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Roth Capital upped their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. Oppenheimer upped their price objective on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, November 25th. Finally, ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $69.54.
CRSP stock opened at $65.95 on Monday. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $3.61 billion, a price-to-earnings ratio of -19.17 and a beta of 3.30. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The firm has a 50 day moving average of $61.00 and a two-hundred day moving average of $49.02.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, research analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In related news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,118 shares of company stock valued at $3,620,760. Corporate insiders own 21.40% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. raised its stake in Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after purchasing an additional 906,006 shares during the last quarter. Orbimed Advisors LLC acquired a new position in Crispr Therapeutics during the 3rd quarter valued at $21,167,000. Price T Rowe Associates Inc. MD raised its stake in Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN raised its stake in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after purchasing an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in Crispr Therapeutics during the 2nd quarter valued at $5,165,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Find a Trading Strategy That Works
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.